Epidemiology, Disease Severity and Outcome of Severe Acute Respiratory Syndrome Coronavirus 2 and Influenza Viruses Coinfection Seen at Egypt Integrated Acute Respiratory Infections Surveillance, 2020-2022.
Journal
The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale
ISSN: 1712-9532
Titre abrégé: Can J Infect Dis Med Microbiol
Pays: Egypt
ID NLM: 101226876
Informations de publication
Date de publication:
2022
2022
Historique:
received:
02
08
2022
revised:
14
10
2022
accepted:
25
10
2022
entrez:
28
11
2022
pubmed:
29
11
2022
medline:
29
11
2022
Statut:
epublish
Résumé
Cocirculation of influenza (Flu) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (SARS-CoV-2/Flu) represent a public health concern as it may worsen the severity and increase fatality from coronavirus disease 2019. An increase in the number of patients with coinfection was recently reported. We studied epidemiology, severity, and outcome of patients with SARS-CoV-2/Flu coinfection seen at Egypt's integrated acute respiratory infections surveillance to better describe disease impact and guide effective preventive measures. The first two outpatients were seen daily, and every fifth patient admitted to 19 sentinel hospitals with respiratory symptoms was enrolled. Patients were interviewed using a standardized questionnaire and provided nasopharyngeal swabs to be tested for SARS-CoV-2 and influenza by real-time polymerase chain reaction at the central laboratory. Data from all patients with coinfection were obtained, and descriptive data analysis was performed for patients' demographics, clinical course, and outcome. The total number of patients enrolled between January 2020 and April 2022 was 18,160 and 6,453 (35.5%) tested positive for viruses, including 52 (0.8%) coinfection. Of them, 36 (69.2%) were coinfected with Flu A/H3, 9 (17.3%) Flu-B, and 7 (13.5%) Flu A/H1. Patients' mean age was 33.2 ± 21, 55.8% were males, and 20 (38.5%) were hospitalized, with mean hospital days 6.7 ± 6. At the hospital, 14 (70.0%) developed pneumonia, 6 (30.0%) ICU admitted, and 4 (20.0%) died. The hospitalization rate among patients coinfected with Flu-B and Flu A/H3 was 55.6 and 41.7%, with mean hospital days (8.0 ± 6 and 6.4 ± 6), pneumonia infection (40.0 and 80.0%), ICU admission (40.0 and 26.7%), and death (20.0% for both), while no patients hospitalized with A/H1. The recent increase in the number of SARS-CoV-2/Flu coinfections was identified in Egypt. The disease could have a severe course and high fatality, especially in those coinfected with Flu-B and Flu A/H3. Monitoring disease severity and impact is required to guide preventive strategy.
Sections du résumé
Background
UNASSIGNED
Cocirculation of influenza (Flu) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (SARS-CoV-2/Flu) represent a public health concern as it may worsen the severity and increase fatality from coronavirus disease 2019. An increase in the number of patients with coinfection was recently reported. We studied epidemiology, severity, and outcome of patients with SARS-CoV-2/Flu coinfection seen at Egypt's integrated acute respiratory infections surveillance to better describe disease impact and guide effective preventive measures.
Methods
UNASSIGNED
The first two outpatients were seen daily, and every fifth patient admitted to 19 sentinel hospitals with respiratory symptoms was enrolled. Patients were interviewed using a standardized questionnaire and provided nasopharyngeal swabs to be tested for SARS-CoV-2 and influenza by real-time polymerase chain reaction at the central laboratory. Data from all patients with coinfection were obtained, and descriptive data analysis was performed for patients' demographics, clinical course, and outcome.
Results
UNASSIGNED
The total number of patients enrolled between January 2020 and April 2022 was 18,160 and 6,453 (35.5%) tested positive for viruses, including 52 (0.8%) coinfection. Of them, 36 (69.2%) were coinfected with Flu A/H3, 9 (17.3%) Flu-B, and 7 (13.5%) Flu A/H1. Patients' mean age was 33.2 ± 21, 55.8% were males, and 20 (38.5%) were hospitalized, with mean hospital days 6.7 ± 6. At the hospital, 14 (70.0%) developed pneumonia, 6 (30.0%) ICU admitted, and 4 (20.0%) died. The hospitalization rate among patients coinfected with Flu-B and Flu A/H3 was 55.6 and 41.7%, with mean hospital days (8.0 ± 6 and 6.4 ± 6), pneumonia infection (40.0 and 80.0%), ICU admission (40.0 and 26.7%), and death (20.0% for both), while no patients hospitalized with A/H1.
Conclusions
UNASSIGNED
The recent increase in the number of SARS-CoV-2/Flu coinfections was identified in Egypt. The disease could have a severe course and high fatality, especially in those coinfected with Flu-B and Flu A/H3. Monitoring disease severity and impact is required to guide preventive strategy.
Identifiants
pubmed: 36437892
doi: 10.1155/2022/7497500
pmc: PMC9691288
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7497500Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
Copyright © 2022 Manal Fahim et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Sci Rep. 2021 Oct 28;11(1):21259
pubmed: 34711897
East Mediterr Health J. 2016 Oct 02;22(7):527-536
pubmed: 27714747
Clin Infect Dis. 2021 Jun 15;72(12):e993-e994
pubmed: 33277660
Influenza Other Respir Viruses. 2021 Sep;15(5):589-598
pubmed: 33960675
Nat Commun. 2021 Oct 5;12(1):5819
pubmed: 34611155
Virol J. 2021 Jun 14;18(1):127
pubmed: 34127006
Crit Rev Clin Lab Sci. 2022 Nov;59(7):445-459
pubmed: 35289222
Lancet Microbe. 2020 Sep;1(5):e199
pubmed: 33521723
J Clin Microbiol. 2004 Apr;42(4):1564-9
pubmed: 15071005
J Med Virol. 2020 Nov;92(11):2319-2321
pubmed: 32410338
Front Med (Lausanne). 2021 Jun 25;8:681469
pubmed: 34249971
Pediatr Infect Dis J. 2020 Jun;39(6):489-493
pubmed: 32091502
Influenza Other Respir Viruses. 2021 Sep;15(5):573-576
pubmed: 33955176
Cell Res. 2021 Apr;31(4):395-403
pubmed: 33603116
J Med Virol. 2020 Nov;92(11):2870-2873
pubmed: 32530499
BMJ Open. 2021 Nov 29;11(11):e053768
pubmed: 34845073
J Med Virol. 2020 Nov;92(11):2489-2497
pubmed: 32530531
Int J Epidemiol. 2021 Aug 30;50(4):1124-1133
pubmed: 33942104
Int J Infect Dis. 2020 Aug;97:236-239
pubmed: 32565366
JMIR Public Health Surveill. 2021 Apr 28;7(4):e27433
pubmed: 33784634
Front Public Health. 2021 Dec 10;9:773130
pubmed: 34957025